Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1220811 | 0.89 | MEN1 (0.41) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL1220897 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL1222362 | 0.83 | CHRNA7 (0.54) | SLC6A2SLC6A4SLC6A3CHRNA7SIGMAR1 | |
| SCHEMBL1220797 | 0.81 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL1220771 | 0.81 | CHRNA7 (0.47) | SLC6A2SLC6A4SLC6A3CHRNA7SIGMAR1 | |
| SCHEMBL12586345 | 0.81 | SIGMAR1 (0.44) | SLC6A2SLC6A4SLC6A3CHRNA7SIGMAR1 | |
| SCHEMBL1221854 | 0.81 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CHRNA7SIGMAR1 | |
| SCHEMBL1221561 | 0.79 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL1220895 | 0.77 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL19157213 | 0.77 | TACR1 (0.45) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046179-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-02-24 | — | — | US | claimed |
| US-20110046179-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-02-24 | — | — | US | disclosed |
| US-20110046179-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-02-24 | — | — | US | disclosed |
| US-20110046179-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-02-24 | — | — | US | disclosed |
| EP-2059506-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008025777-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025777-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046179-A1 | NOVEL PIPERIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | SLC6A2 3/4885SLC6A4 5/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.